Nevro - NVRO Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Hold
Consensus Price Target: $26.67
Forecasted Upside: 42.68%
Number of Analysts: 12
Breakdown:
1 Sell Ratings
7 Hold Ratings
4 Buy Ratings
0 Strong Buy Ratings

^$18.69 As of 12/5/2023 11:55 AM ET

▼ -0.19 (-1.01%)

1 month | 3 months | 12 months

Get New Nevro Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for NVRO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NVRO

^$26.67

▲ +42.68% Upside Potential

This price target is based on 12 analysts offering 12 month price targets for Nevro in the last 3 months. The average price target is $26.67, with a high forecast of $57.00 and a low forecast of $15.00. The average price target represents a 42.68% upside from the last price of $18.69.

Current Consensus is Hold

The current consensus among 12 contributing investment analysts is to hold stock in Nevro. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
4 buy ratings
7 hold ratings
1 sell ratings

Ratings as of

6/12/2022

0 strong buy ratings
4 buy ratings
7 hold ratings
1 sell ratings

Ratings as of

9/10/2022

0 strong buy ratings
4 buy ratings
7 hold ratings
1 sell ratings

Ratings as of

12/9/2022

0 strong buy ratings
4 buy ratings
7 hold ratings
1 sell ratings

Ratings as of

3/9/2023

0 strong buy ratings
4 buy ratings
7 hold ratings
1 sell ratings

Ratings as of

6/7/2023

0 strong buy ratings
4 buy ratings
7 hold ratings
1 sell ratings

Ratings as of

9/5/2023

0 strong buy ratings
4 buy ratings
7 hold ratings
1 sell ratings

Ratings as of

11/4/2023

0 strong buy ratings
4 buy ratings
7 hold ratings
1 sell ratings

Ratings as of

12/4/2023

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
12/1/2023	Royal Bank of Canada	Reiterated Rating	Outperform ➝ Outperform	$23.00	Low
11/3/2023	Truist Financial	Lower Target	Hold ➝ Hold	$18.50 ➝ $17.00	Low
11/2/2023	Morgan Stanley	Lower Target	Equal Weight ➝ Equal Weight	$23.00 ➝ $18.00	N/A
11/2/2023	Piper Sandler	Lower Target	Underweight ➝ Underweight	$24.00 ➝ $15.00	N/A
11/2/2023	JPMorgan Chase & Co.	Lower Target	Neutral ➝ Neutral	$23.00 ➝ $18.00	Low
8/21/2023	Citigroup	Lower Target	Neutral ➝ Neutral	$24.00 ➝ $21.00	Low
8/17/2023	Royal Bank of Canada	Reiterated Rating	Outperform ➝ Outperform	$33.00	Low
8/3/2023	Truist Financial	Lower Target	Hold ➝ Hold	$27.00 ➝ $25.00	Low
8/2/2023	Oppenheimer	Lower Target	Outperform ➝ Outperform	$40.00 ➝ $35.00	Low
8/2/2023	Wells Fargo & Company	Lower Target	Equal Weight ➝ Equal Weight	$27.00 ➝ $23.00	Low
8/2/2023	Morgan Stanley	Lower Target	Equal Weight ➝ Equal Weight	$29.00 ➝ $23.00	N/A
8/2/2023	JPMorgan Chase & Co.	Lower Target	Neutral ➝ Neutral	$28.00 ➝ $23.00	N/A
8/2/2023	Canaccord Genuity Group	Lower Target	Buy ➝ Buy	$68.00 ➝ $57.00	Low
8/2/2023	Royal Bank of Canada	Lower Target	Outperform ➝ Outperform	$39.00 ➝ $33.00	Low
8/2/2023	Robert W. Baird	Lower Target	Neutral ➝ Neutral	$26.00 ➝ $23.00	Low
8/2/2023	JMP Securities	Lower Target	Outperform ➝ Outperform	$75.00 ➝ $40.00	Low
7/19/2023	Truist Financial	Lower Target	Hold	$30.00 ➝ $27.00	Low
7/18/2023	Robert W. Baird	Initiated Coverage	Neutral	$26.00	Low
7/17/2023	Mizuho	Lower Target		$40.00 ➝ $30.00	Low
6/28/2023	JPMorgan Chase & Co.	Lower Target		$40.00 ➝ $28.00	Low
6/7/2023	Citigroup	Lower Target		$37.00 ➝ $27.00	Low
6/6/2023	Truist Financial	Lower Target		$32.00 ➝ $30.00	Low
5/31/2023	Royal Bank of Canada	Initiated Coverage	Outperform	$40.00	Low
5/18/2023	Truist Financial	Lower Target		$40.00 ➝ $32.00	Low
5/15/2023	Oppenheimer	Upgrade	Market Perform ➝ Outperform	$40.00	Low
4/27/2023	Piper Sandler	Lower Target		$37.00 ➝ $34.00	Low
4/17/2023	Truist Financial	Lower Target	Hold	$42.00 ➝ $40.00	Low
4/13/2023	Mizuho	Initiated Coverage	Neutral	$40.00	Low
2/6/2023	Canaccord Genuity Group	Boost Target	Buy	$67.00 ➝ $72.00	Low
1/26/2023	Piper Sandler	Lower Target	Underweight	$38.00 ➝ $37.00	Low
1/17/2023	Citigroup	Downgrade	Buy ➝ Neutral	$40.00	Low
1/11/2023	Wells Fargo & Company	Lower Target	Equal Weight	$43.00 ➝ $37.00	Low
1/6/2023	Morgan Stanley	Lower Target	Equal Weight	$49.00 ➝ $46.00	Low
1/6/2023	Piper Sandler	Downgrade	Neutral ➝ Underweight	$42.00 ➝ $38.00	N/A
12/20/2022	Truist Financial	Lower Target	Hold	$45.00 ➝ $41.00	Low
12/20/2022	Canaccord Genuity Group	Upgrade	Hold ➝ Buy	$41.00 ➝ $67.00	Low
12/12/2022	Wells Fargo & Company	Downgrade	Overweight ➝ Equal Weight	$66.00 ➝ $43.00	Low
11/3/2022	JPMorgan Chase & Co.	Lower Target	Neutral	$50.00 ➝ $40.00	Low
11/3/2022	Piper Sandler	Lower Target	Neutral	$45.00 ➝ $42.00	Low
11/2/2022	William Blair	Reiterated Rating	Market Perform		Low
10/12/2022	Jefferies Financial Group	Initiated Coverage	Underperform	$31.00	Low
10/11/2022	Morgan Stanley	Lower Target	Equal Weight	$54.00 ➝ $49.00	Low
8/4/2022	Morgan Stanley	Lower Target	Equal Weight	$55.00 ➝ $54.00	N/A
8/4/2022	Wells Fargo & Company	Lower Target	Overweight	$90.00 ➝ $86.00	Low
8/4/2022	Piper Sandler	Lower Target	Neutral	$64.00 ➝ $45.00	Low
7/22/2022	Truist Financial	Lower Target		$45.00	Low
6/7/2022	Morgan Stanley	Lower Target	Equal Weight	$74.00 ➝ $55.00	Low
5/26/2022	JMP Securities	Lower Target	Market Outperform	$125.00 ➝ $95.00	Low
5/17/2022	Citigroup	Lower Target		$78.00 ➝ $68.00	N/A
5/5/2022	Citigroup	Upgrade	Neutral ➝ Buy	$78.00	High
5/5/2022	Piper Sandler	Lower Target		$65.00 ➝ $64.00	High
4/5/2022	Wolfe Research	Initiated Coverage	Underperform	$64.00	High
3/2/2022	Bank of America	Initiated Coverage	Underperform ➝ Underperform		High
2/25/2022	Morgan Stanley	Lower Target	Equal Weight	$100.00 ➝ $76.00	High
2/25/2022	Canaccord Genuity Group	Lower Target	Hold ➝ Hold	$97.00 ➝ $72.00	High
2/24/2022	SVB Leerink	Lower Target	Outperform	$105.00 ➝ $85.00	High
2/24/2022	Wells Fargo & Company	Lower Target	Overweight	$116.00 ➝ $90.00	High
2/24/2022	Piper Sandler	Lower Target	Neutral	$92.00 ➝ $65.00	High
1/12/2022	Canaccord Genuity Group	Lower Target	Hold ➝ Hold	$118.00 ➝ $97.00	Low
1/7/2022	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$140.00 ➝ $100.00	High
1/3/2022	Piper Sandler	Lower Target		$115.00 ➝ $90.00	High
12/21/2021	Truist Financial	Lower Target	Hold	$105.00 ➝ $95.00	High
12/6/2021	Wells Fargo & Company	Upgrade	Equal Weight ➝ Overweight	$116.00	High
11/19/2021	SVB Leerink	Reiterated Rating	Buy	$128.00	High
11/9/2021	Truist Financial	Downgrade	Buy ➝ Hold	$165.00 ➝ $105.00	High
11/9/2021	Wells Fargo & Company	Lower Target	Equal Weight	$122.00 ➝ $116.00	High
11/9/2021	Citigroup	Lower Target	Neutral	$125.00 ➝ $120.00	High
11/9/2021	Piper Sandler	Lower Target	In-Line ➝ Neutral	$125.00 ➝ $115.00	High
11/9/2021	SVB Leerink	Lower Target	Outperform	$147.00 ➝ $128.00	High
8/5/2021	Truist Financial	Lower Target	Positive ➝ Buy	$205.00 ➝ $165.00	High
8/5/2021	Morgan Stanley	Lower Target	Overweight	$199.00 ➝ $150.00	High
8/5/2021	SVB Leerink	Lower Target	Outperform	$210.00 ➝ $147.00	High
8/5/2021	JMP Securities	Lower Target	Outperform	$190.00 ➝ $160.00	High
8/5/2021	William Blair	Downgrade	Outperform ➝ Market Perform		High
8/5/2021	Wells Fargo & Company	Downgrade	Overweight ➝ Equal Weight	$122.00	High
8/5/2021	Citigroup	Downgrade	Buy ➝ Neutral	$198.00 ➝ $125.00	High
8/5/2021	Piper Sandler	Downgrade	Overweight ➝ Neutral	$200.00 ➝ $125.00	High
7/9/2021	Redburn Partners	Downgrade	Buy ➝ Neutral		Low
7/6/2021	Robert W. Baird	Downgrade	Outperform ➝ Neutral	$188.00 ➝ $150.00	High
7/2/2021	SVB Leerink	Reiterated Rating	Buy		Medium
6/28/2021	Wells Fargo & Company	Lower Target	Overweight	$215.00 ➝ $202.00	Medium
6/28/2021	Robert W. Baird	Lower Target	Outperform	$200.00 ➝ $188.00	High
6/28/2021	Piper Sandler	Boost Target	Overweight	$190.00 ➝ $200.00	High
3/4/2021	SVB Leerink	Reiterated Rating	Buy		High
2/26/2021	Morgan Stanley	Boost Target	Overweight	$192.00 ➝ $199.00	Low
2/2/2021	Piper Sandler	Initiated Coverage	Overweight	$190.00	N/A
1/19/2021	SVB Leerink	Boost Target	Positive ➝ Outperform	$190.00 ➝ $210.00	Medium
1/6/2021	Truist Financial	Boost Target		$175.00 ➝ $205.00	N/A
1/5/2021	Robert W. Baird	Boost Target	Outperform	$180.00 ➝ $200.00	N/A
1/4/2021	Wells Fargo & Company	Boost Target	Overweight	$177.00 ➝ $215.00	N/A
12/31/2020	Guggenheim	Boost Target	Buy	$190.00 ➝ $205.00	N/A
12/15/2020	Morgan Stanley	Boost Target	Overweight	$161.00 ➝ $192.00	Medium
11/11/2020	JMP Securities	Reiterated Rating	Outperform	$150.00 ➝ $190.00	Low
11/6/2020	Morgan Stanley	Boost Target	Overweight	$150.00 ➝ $161.00	Low
10/22/2020	Guggenheim	Initiated Coverage	Buy	$190.00	Low
10/21/2020	OTR Global	Upgrade	Positive		Low
10/12/2020	SVB Leerink	Boost Target	Outperform	$165.00 ➝ $175.00	Low
9/1/2020	Robert W. Baird	Initiated Coverage	Outperform	$160.00	Low
8/6/2020	Morgan Stanley	Boost Target	Overweight	$145.00 ➝ $150.00	Medium
8/6/2020	Wells Fargo & Company	Boost Target	Overweight	$141.00 ➝ $153.00	High
8/6/2020	SVB Leerink	Boost Target	Outperform	$140.00 ➝ $165.00	High
8/6/2020	Citigroup	Boost Target	Buy	$137.00 ➝ $160.00	High
8/5/2020	Oppenheimer	Initiated Coverage	Hold		High
6/18/2020	Morgan Stanley	Boost Target		$135.00 ➝ $145.00	High
6/18/2020	Citigroup	Boost Target	Overweight	$135.00 ➝ $145.00	High
6/8/2020	UBS Group	Upgrade	Sell ➝ Neutral	$100.00 ➝ $132.00	High
6/4/2020	SunTrust Banks	Reiterated Rating	Buy	$135.00	High
5/6/2020	SunTrust Banks	Boost Target	Buy	$120.00 ➝ $135.00	Medium
5/6/2020	Morgan Stanley	Boost Target	Overweight	$113.00 ➝ $135.00	Medium
5/6/2020	JPMorgan Chase & Co.	Boost Target	Neutral	$90.00 ➝ $100.00	Low
5/6/2020	Citigroup	Boost Target	Buy	$130.00 ➝ $137.00	Low
4/3/2020	Morgan Stanley	Lower Target	Overweight	$118.00 ➝ $113.00	Low
4/2/2020	JPMorgan Chase & Co.	Lower Target	Neutral	$130.00 ➝ $90.00	High
4/2/2020	SunTrust Banks	Lower Target	Buy	$146.00 ➝ $120.00	High
4/2/2020	Wells Fargo & Company	Lower Target	Overweight	$158.00 ➝ $126.00	High
3/27/2020	Morgan Stanley	Lower Target	Overweight	$142.00 ➝ $118.00	Low
3/27/2020	Citigroup	Lower Target	Buy	$160.00 ➝ $130.00	High
3/4/2020	Citigroup	Initiated Coverage	Buy	$160.00	Low
2/26/2020	SVB Leerink	Boost Target	Outperform ➝ Positive	$146.00 ➝ $158.00	High
2/26/2020	Wells Fargo & Company	Boost Target	Overweight	$144.00 ➝ $158.00	High
2/26/2020	JPMorgan Chase & Co.	Boost Target	Neutral	$96.00 ➝ $130.00	High
1/27/2020	Morgan Stanley	Boost Target	Overweight	$125.00 ➝ $142.00	High
1/27/2020	JMP Securities	Boost Target	Outperform	$115.00 ➝ $150.00	High
1/21/2020	Wells Fargo & Company	Boost Target	Overweight	$135.00 ➝ $144.00	Low
1/15/2020	UBS Group	Boost Target	Sell	$77.00 ➝ $84.00	High
1/7/2020	SunTrust Banks	Initiated Coverage	Buy	$132.00	Low
1/6/2020	Oppenheimer	Reiterated Rating	Outperform ➝ Market Perform		N/A
12/20/2019	JPMorgan Chase & Co.	Boost Target	Neutral	$80.00 ➝ $96.00	Low
12/17/2019	Morgan Stanley	Boost Target	Overweight	$100.00 ➝ $125.00	Low
11/7/2019	Oppenheimer	Upgrade	Market Perform ➝ Outperform	$106.00	High
11/7/2019	Wells Fargo & Company	Boost Target	Outperform	$86.00 ➝ $105.00	High
11/7/2019	JMP Securities	Boost Target	Outperform	$115.00	High
10/22/2019	Oppenheimer	Initiated Coverage	Market Perform		High
10/9/2019	Wells Fargo & Company	Boost Target	Outperform	$70.00 ➝ $86.00	Low
8/23/2019	SVB Leerink	Set Target	Buy	$98.00	Medium
8/12/2019	JMP Securities	Boost Target	Market Outperform	$70.00 ➝ $90.00	High
8/9/2019	Morgan Stanley	Set Target	Buy	$76.00	Medium
8/9/2019	Northland Securities	Set Target	Hold	$65.00	Medium
8/9/2019	Bank of America	Boost Target	Buy	$70.00 ➝ $74.00	N/A
5/13/2019	Wells Fargo & Company	Lower Target	Outperform	$75.00 ➝ $70.00	Low
5/10/2019	Morgan Stanley	Lower Target	Overweight	$70.00 ➝ $64.00	High
5/10/2019	JMP Securities	Lower Target	Market Outperform	$80.00 ➝ $70.00	High
3/20/2019	Morgan Stanley	Upgrade	Underweight ➝ Overweight	$41.00 ➝ $70.00	High
3/20/2019	Wells Fargo & Company	Upgrade	Market Perform ➝ Outperform	$75.00	High
3/20/2019	Bank of America	Upgrade	Neutral ➝ Buy	$50.00 ➝ $70.00	High
3/19/2019	BMO Capital Markets	Upgrade	Market Perform ➝ Outperform	$46.00 ➝ $67.00	High
2/22/2019	BMO Capital Markets	Downgrade	Outperform ➝ Market Perform		High
1/11/2019	Northland Securities	Reiterated Rating	Hold	$48.00	Low
1/2/2019	Morgan Stanley	Lower Target	Underweight ➝ Underweight	$43.00 ➝ $38.00	High

(Data available from 12/5/2018 forward)

News Sentiment Rating

0.05 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

3 very positive mentions
8 positive mentions
1 negative mentions
1 very negative mentions

Mentions as of

5/9/2023

8 very positive mentions
14 positive mentions
4 negative mentions
0 very negative mentions

Mentions as of

6/8/2023

4 very positive mentions
6 positive mentions
0 negative mentions
1 very negative mentions

Mentions as of

7/8/2023

7 very positive mentions
10 positive mentions
1 negative mentions
1 very negative mentions

Mentions as of

8/7/2023

11 very positive mentions
4 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

9/6/2023

2 very positive mentions
2 positive mentions
1 negative mentions
2 very negative mentions

Mentions as of

10/6/2023

3 very positive mentions
6 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

11/5/2023

1 very positive mentions
7 positive mentions
1 negative mentions
1 very negative mentions

Mentions as of

12/5/2023

Current Sentiment

Recent Stories by Sentiment

Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation system for the treatment of chronic pain, as well as Senza II and Senza Omnia SCS systems. It also provides 10 kHz Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company's Senza HFX iQ IPG system includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system. In addition, it offers surpass surgical and percutaneous leads. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was incorporated in 2006 and is headquartered in Redwood City, California.

Today's Range

Now: $18.69

$18.39

$18.90

50 Day Range

MA: $16.80

$14.18

$19.68

52 Week Range

Now: $18.69

$13.98

$43.83

Volume

385,125 shs

Average Volume

579,311 shs

Market Capitalization

$676.76 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.95

Frequently Asked Questions

What sell-side analysts currently cover shares of Nevro?: The following Wall Street research analysts have issued stock ratings on Nevro in the last year: Canaccord Genuity Group Inc., Citigroup Inc., JMP Securities, JPMorgan Chase & Co., Mizuho, Morgan Stanley, Oppenheimer Holdings Inc., Piper Sandler, Robert W. Baird, Royal Bank of Canada, StockNews.com, Truist Financial Co., and Wells Fargo & Company.
View the latest analyst ratings for NVRO.
What is the current price target for Nevro?: 12 Wall Street analysts have set twelve-month price targets for Nevro in the last year. Their average twelve-month price target is $26.67, suggesting a possible upside of 42.7%. Canaccord Genuity Group Inc. has the highest price target set, predicting NVRO will reach $57.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $15.00 for Nevro in the next year.
View the latest price targets for NVRO.
What is the current consensus analyst rating for Nevro?: Nevro currently has 1 sell rating, 7 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in NVRO, but not buy more shares or sell existing shares.
View the latest ratings for NVRO.
What other companies compete with Nevro?: Other companies that are similar to Nevro include Treace Medical Concepts, OraSure Technologies, Atrion, IRadimed and Artivion. Learn More about companies similar to Nevro.
How do I contact Nevro's investor relations team?: Nevro's physical mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The medical equipment provider's listed phone number is (650) 251-0005 and its investor relations email address is [email protected]. The official website for Nevro is www.nevro.com. Learn More about contacing Nevro investor relations.

Nevro - NVRO Stock Price Target and Predictions

Analyst Price Target for NVRO

Current Consensus is Hold

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.05 (Hold)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Nevro?

What is the current price target for Nevro?

What is the current consensus analyst rating for Nevro?

What other companies compete with Nevro?

How do I contact Nevro's investor relations team?